EVALUATION OF CEFOPERAZONE/SULBACTAM AND VITAMIN K USE IN PATIENTS WITH BACTERIAL INFECTIONS

  • THEERAPONG SEESIN Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand.
  • PITIPONG PENGSUPSIN Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand.
  • SARAWUT WEESAPHEN Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand.
  • PEERAYA SRIPHONG Department of Clinical Pharmacy, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand.
  • UAEPONG LIMPAPANASIT Department of Internal Medicine, Mahasarakham Hospital, Muang Maha Sarakham, Maha Sarakham, Thailand.
  • SIRIN BHONGCHIRAWATTANA Department of Pharmacy, Mahasarakham Hospital, Muang Maha Sarakham, Maha Sarakham, Thailand.

Abstract

Objective: The objectives of this study were to evaluate the effects of Vitamin K use for bleeding or coagulopathies prevention and to assess the
occurrence of drug-related problems in patients receiving cefoperazone/sulbactam.
Methods: The prospective study was conducted between January and April 2018 at 5 general medicine wards in Mahasarakham Hospital, Thailand.
Patients above 18 years of age with bacterial infections who received cefoperazone/sulbactam concurrent with Vitamin K were included. Rate of
bleeding, coagulopathies, and drug-related problems were evaluated.
Results: Forty-three eligible patients enrolled in this study. Most were women (72.1%), average ages were 64.7 years old and 93.0% had comorbidities
(most were diabetes, hypertension, and chronic kidney disease). High doses of cefoperazone/sulbactam have been used in 35 patients (81.4%).
Gastrointestinal bleeding occurred in one patient (8.3%), 24 patients had prolonged prothrombin time (55.8%), and 8 patients had prolonged
activated partial thromboplastin time (18.6%). Anticipated risk factors were not associated with bleeding. Drug-related problems were missing of
dose adjustment for cefoperazone/sulbactam in patients with renal impairment (4.7%), drug interactions between warfarin and Vitamin K (4.7%),
and drug allergy (2.3%).
Conclusion: This study found that cefoperazone/sulbactam aggravated bleeding and coagulopathies despite using Vitamin K for prevention. We
support the use of Vitamin K for the prevention of bleeding in high-risk patient such as elderly who receive cefoperazone/sulbactam.

Keywords: Cefoperazone/sulbactam, Vitamin K, Bleeding, Coagulopathies

References

1. Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D,
et al. Mechanism of cephalosporin-induced hypoprothrombinemia:
Relation to cephalosporin side chain, Vitamin K metabolism, and
vitamin K status. J Clin Pharmacol 1988;28:88-95.
2. Strom BL, Schinnar R, Gibson GA, Brennan PJ, Berlin JA. Risk of
bleeding and hypoprothrombinaemia associated with NMTT side chain
antibiotics: Using cefoperazone as a test case. Pharmacoepidemiol
Drug Saf 1999;8:81-94.
3. Katukuri GR, Maddala RN, Ramamoorthi K, Hande M. Cefoperazone
induced gastrointestinal bleeding. J Clin Diagn Res 2016;10:OD10-1.
4. Rockoff SD, Blumenfrucht MJ, Irwin RJ Jr., Eng RH. Vitamin K
supplementation during prophylactic use of cefoperazone in urologic
surgery. Infection 1992;20:146-8.
5. Apisarnthanarak A, Mundy LM. Mortality associated with pandrugresistant
Acinetobacter baumannii infections in Thailand. Am J Infect
Control 2009;37:519-20.
6. Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J, et al. Sulbactam-based
therapy for Acinetobacter baumannii infection: A systematic review
and meta-analysis. Braz J Infect Dis 2013;17:389-94.
7. Qin Y, Zhang J, Wu L, Zhang D, Fu L, Xue X, et al. Comparison of the
treatment efficacy between tigecycline plus high-dose cefoperazonesulbactam
and tigecycline monotherapy against ventilator-associated
pneumonia caused by extensively drug-resistant Acinetobacter
baumannii. Int J Clin Pharmacol Ther 2018;56:120-9.
Statistics
51 Views | 48 Downloads
Citatons
How to Cite
SEESIN, T., PENGSUPSIN, P., WEESAPHEN, S., SRIPHONG, P., LIMPAPANASIT, U., & BHONGCHIRAWATTANA, S. (2019). EVALUATION OF CEFOPERAZONE/SULBACTAM AND VITAMIN K USE IN PATIENTS WITH BACTERIAL INFECTIONS. International Journal of Applied Pharmaceutics, 11(5), 191-193. https://doi.org/10.22159/ijap.2019.v11s5.T0100
Section
Original Article(s)